SpectraCure AB (SE:SPEC)
:SPEC
SPEC Stock Chart & Stats
kr0.18
kr0.10(5.82%)
At close: 4:00 PM EST
kr0.18
kr0.10(5.82%)
Day’s Range― - ―
52-Week Rangekr0.08 - kr1.19
Previous CloseN/A
Volume60.95K
Average Volume (3M)1.15M
Market Cap
kr48.50M
Enterprise Valuekr24.30M
Total Cash (Recent Filing)kr13.53M
Total Debt (Recent Filing)kr3.01M
Price to Earnings (P/E)―
Beta-0.47
Next Earnings
May 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding570,602,840
10 Day Avg. Volume1,242,664
30 Day Avg. Volume1,152,681
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.68
Price to Sales (P/S)0.00
P/FCF Ratio-2.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageLow absolute debt relative to equity reduces financing fixed-cost burden and preserves balance-sheet flexibility over the medium term. With modest leverage the company can pursue additional funding or partnerships without high interest expense, supporting continued clinical development and strategic optionality.
Differentiated Platform OfferingThe IDOSE platform integrates treatment planning, monitoring and light-delivery for interstitial PDT, representing a differentiated, integrated medical-device solution. A platform approach creates durable clinical specialization, potential IP protection and a pathway to expand into other solid tumors beyond prostate over time.
Lean Operating StructureA compact team suggests lower fixed overhead and focused R&D execution, which can extend operational runway per financing round. Lean operations help allocate scarce capital to clinical milestones and make organizational pivots or partnership integrations less disruptive over the next several months.
Bears Say
Minimal Revenue And Widening LossesThe company remains effectively pre-commercial with negligible revenue while losses have widened materially. Without scalable revenue to absorb R&D and operating costs, sustained negative profitability undermines internal funding capacity and increases reliance on external capital to reach commercialization milestones.
Negative Free Cash Flow / Accelerating BurnConsistently negative and worsening free cash flow signals accelerating cash consumption from operations. This structural burn requires repeated external financing or partnership deals, creating execution risk, potential dilution, and constraints on timelines for regulatory approvals and commercial launch.
Eroding Equity Base / Funding DependenceA declining equity base over multiple years reflects cumulative negative earnings and prior financing use. Shrinking reserves reduce the cushion for prolonged development cycles, increase leverage on future funding rounds, and heighten vulnerability to adverse financing terms or strategic dilution if losses persist.
SPEC FAQ
What was SpectraCure AB’s price range in the past 12 months?
SpectraCure AB lowest stock price was kr0.08 and its highest was kr1.19 in the past 12 months.
What is SpectraCure AB’s market cap?
SpectraCure AB’s market cap is kr48.50M.
When is SpectraCure AB’s upcoming earnings report date?
SpectraCure AB’s upcoming earnings report date is May 19, 2026 which is in 39 days.
How were SpectraCure AB’s earnings last quarter?
SpectraCure AB released its earnings results on Feb 19, 2026. The company reported -kr0.018 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.018.
Is SpectraCure AB overvalued?
According to Wall Street analysts SpectraCure AB’s price is currently Overvalued.
Does SpectraCure AB pay dividends?
SpectraCure AB does not currently pay dividends.
What is SpectraCure AB’s EPS estimate?
SpectraCure AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SpectraCure AB have?
SpectraCure AB has 570,602,840 shares outstanding.
What happened to SpectraCure AB’s price movement after its last earnings report?
SpectraCure AB reported an EPS of -kr0.018 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of SpectraCure AB?
Currently, no hedge funds are holding shares in SE:SPEC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SpectraCure AB
SpectraCure AB (SPEC) is a medical technology company operating primarily in the field of cancer treatment. The company specializes in developing and commercializing innovative systems for photodynamic therapy (PDT), a minimally invasive treatment approach that uses light-sensitive drugs to target and destroy cancer cells. SpectraCure's core product is its proprietary interstitial PDT (IPDT) system, designed to treat solid tumors such as prostate cancer. The company is committed to advancing cancer care by providing effective and less invasive treatment options.